Not Signed In - Positive Preliminary Results From A Phase 2a Clinical Trial Of XP19986 As A Treatment For Gastroesophageal Reflux Disease
Tue, 23 May 2006 06:00 AM EST
... SANTA CLARA, Calif., May 22 /PRNewswire-FirstCall/ -- XenoPort, Inc.(Nasdaq: XNPT) announced today preliminary top-line results of a Phase 2aclinical trial indicating that single doses of XP19986 were well toleratedand produced statistically significant reductions in the number of refluxepisodes in patients with gastroesophageal reflux disease, or GERD. [click link for full article] ...
Related Topics
- Clinical Trials
- GERD
- Gastroesophageal Reflux in Infants
- Crohn's Disease
- Esophagitis and Gastroesophageal Reflux
- Gastroesophageal Reflux (GERD)
- Gastroesophageal Reflux in Children and Adolescents
- Infectious Diseases
- Vesicoureteral Reflux
- Interferon Alfa-2a
- Tb
- Peginterferon alfa-2a
- Periodontal Disease
- Pharmacology
- Pancreatic Cancer
- Trastuzumab
- Psychopharmacology
- Vascular Disease
- Addison's Disease
- Digestive Diseases And Disorders
email this page
print this page
bookmark this page
feedback on this page
